Mesenchymal stem cells avoid allogeneic rejection

Journal of Inflammation

Volumn 2, Issue , 2005, Pages

  Ryan, Jennifer M ^a   Barry, Frank P ^b   Murphy, J Mary ^b   Mahon, Bernard P ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; CYTOKINE; HLA ANTIGEN; INTERLEUKIN 10; TRANSFORMING GROWTH FACTOR BETA1;

ALLOGENEIC STEM CELL TRANSPLANTATION; ALLOGRAFT; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; CANCER PATIENT; COCULTURE; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DOWN REGULATION; GRAFT VERSUS HOST REACTION; HUMAN; HURLER SYNDROME; IMMUNE SYSTEM; IMMUNOGENICITY; IMMUNOREGULATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MESENCHYMAL STEM CELL; METACHROMATIC LEUKODYSTROPHY; MIXED LYMPHOCYTE REACTION; MOLECULAR INTERACTION; MOLECULAR RECOGNITION; MYELOABLATIVE CONDITIONING; NATURAL KILLER CELL; OSTEOGENESIS IMPERFECTA; REVIEW; TISSUE REGENERATION;

ANIMALIA;

EID: 25444503061     PISSN: 14769255     EISSN: None     Source Type: Journal    
DOI: 10.1186/1476-9255-2-8     Document Type: Review

References (112)

1. Mosca JD, Hendricks JK, Buyaner D, Davis-Sproul J, Chuang LC, Majumdar MK, Chopra R, Barry F, Murphy M, Thiede MA, Junker U, Rigg RJ, Forestell SP, Bohnlein E, Storb R, Sandmaier BM: Mesenchymal stem cells as vehicles for gene delivery. Clin Orthop Relat Res 2000:S71-90.
2. Barry FP, Murphy JM: Mesenchymal stem cells: clinical applications and biological characterization. Int J Biochem Cell Biol 2004, 36:568-584.
3. Drukker M, Benvenisty N: The immunogenicity of human embryonic stem-derived cells. Trends Biotechnol 2004, 22:136-141.
4. Shizuru JA, Negrin RS, Weissman IL: Hematopoietic stem and progenitor cells: Clinical and Preclinical Regeneration of the Hematolymphoid System. Annu Rev Med 2005, 56:509-538.
5. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR: Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
6. Friedenstein AJP, Petrokova KV: Osteogenesis in transplants of bone marrow cells. Journal of Embyological Experimental Morphology 1966, 16:381-390.
7. Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, Reyes M, Lenvik T, Lund T, Blackstad M, Du J, Aldrich S, Lisberg A, Low WC, Largaespada DA, Verfaillie CM: Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002, 418:41-49.
8. Reyes M, Verfaillie CM: Characterization of multipotent adult progenitor cells, a subpopulation of mesenchymal stem cells. Ann N Y Acad Sci 2001, 938:231-233.
9. Jorgensen C, Gordeladze J, Noel D: Tissue engineering through autologous mesenchymal stem cells. Curr Opin Biotechnol 2004, 15:406-410.
10. Jorgensen C, Djouad F, Apparailly F, Noel D: Engineering mesenchymal stem cells for immunotherapy. Gene Ther 2003, 10:928-931.
11. Pawelec G, Rehbein A, Schlotz E, Friccius H, Pohla H: Cytokine modulation of TH1/TH2 phenotype differentiation in directly alloresponsive CD4+ human T cells. Transplantation 1996, 62:1095-1101.
12. Wood KJ, Sakaguchi S: Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003, 3:199-210.
13. Barry FP, Murphy JM, English K, Mahon BP: Immunogenicity of adult mesenchymal stem cells: lessons from the fetal allograft. Stem cells and development 2005, in press:.
14. Niederkorn JY, Peeler JS, Ross J, Callanan D: The immunogenic privilege of corneal allografts. Reg Immunol 1989, 2:117-124.
15. van den Eynde B, Gaugler B, van der Bruggen P, Coulie P, Brichard V, Boon T: Human tumor antigens recognised by T cells: perspectives for new cancer vaccines. Biochemical Society Transactions 1995, 23:681-686.
16. Koc ON, Day J, Nieder M, Gerson SL, Lazarus HM, Krivit W: Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant 2002, 30:215-222.
17. Koc ON, Gerson SL, Cooper BW, Dyhouse SM, Haynesworth SE, Caplan AI, Lazarus HM: Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 2000, 18:307-316.
18. Horwitz EM, Prockop DJ, Gordon PL, Koo WW, Fitzpatrick LA, Neel MD, McCarville ME, Orchard PJ, Pyeritz RE, Brenner MK: Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta. Blood 2001, 97:1227-1231.
19. Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, Hardy W, Devine S, Ucker D, Deans R, Moseley A, Hoffman R: Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002, 30:42-48.
20. Saito T, Kuang JQ, Bittira B, Al-Khaldi A, Chiu RC: Xenotransplant cardiac chimera: immune tolerance of adult stem cells. Ann Thorac Surg 2002, 74:19-24.
21. Aggarwal S, Pittenger MF: Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005, 105:1815-1822.
22. Deng W, Han Q, Liao L, Li C, Ge W, Zhao Z, You S, Deng H, Zhao RC: Allogeneic bone marrow-derived flk-1+Sca-1- mesenchymal stem cells leads to stable mixed chimerism and donor-specific tolerance. Exp Hematol 2004, 32:861-867.
23. Potian JA, Aviv H, Ponzio NM, Harrison JS, Rameshwar P: Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigens and recall antigens. J Immunol 2003, 171:3426-3434.
24. Zhang W, Ge W, Li C, You S, Liao L, Han Q, Deng W, Zhao RC: Effects of Mesenchymal Stem Cells on Differentiation, Maturation, and Function of Human Monocyte-Derived Dendritic Cells. Stem Cells Dev 2004, 13:263-271.
25. Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E, Dazzi F: Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003, 101:3722-3729.
26. Jiang XX, Zhang Y, Liu B, Zhang SX, Wu Y, Yu XD, Mao N: Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005, in press:.
27. Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringden O: HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 2003, 31:890-896.
28. Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC: Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 2003, 75:389-397.
29. Carlin LM, Eleme K, McCann FE, Davis DM: Intercellular transfer and supramolecular organization of human leukocyte antigen C at inhibitory natural killer cell immune synapses. J Exp Med 2001, 194:1507-1517.
30. Onfelt B, Nedvetzki S, Yanagi K, Davis DM: Cutting edge: Membrane nanotubes connect immune cells. J Immunol 2004, 173:1511-1513.
31. Vanherberghen B, Andersson K, Carlin LM, Nolte-'t Hoen EN, Williams GS, Hoglund P, Davis DM: Human and murine inhibitory natural killer cell receptors transfer from natural killer cells to target cells. Proc Natl Acad Sci U S A 2004, 101:16873-16878.
32. Ruggeri L, Capanni M, Martelli MF, Velardi A: Cellular therapy: exploiting NK cell alloreactivity in transplantation. Curr Opin Hematol 2001, 8:355-359.
33. Hunt JS, Petroff MG, Morales P, Sedlmayr P, Geraghty DE, Ober C: HLA-G in reproduction: studies on the maternal-fetal interface. Hum Immunol 2000, 61:1113-1117.
34. Ristich V, Liang S, Zhang W, Wu J, Horuzsko A: Tolerization of dendritic cells by HLA-G. Eur J Immunol 2005, 35:1133-1142.
35. Moretta L, Moretta A: Killer immunoglobulin-like receptors. Curr Opin Immunol 2004, 16:626-633.
36. Parham P: Killer cell immunoglobulin-like receptor diversity: balancing signals in the natural killer cell response. Immunol Lett 2004, 92:11-13.
37. Gomez-Lozano N, de Pablo R, Puente S, Vilches C: Recognition of HLA-G by the NK cell receptor KIR2DL4 is not essential for human reproduction. Eur J Immunol 2003, 33:639-644.
38. Gotherstrom C, Ringden O, Tammik C, Zetterberg E, Westgren M, Le Blanc K: Immunologic properties of human fetal mesenchymal stem cells. Am J Obstet Gynecol 2004, 190:239-245.
39. Majumdar MK, Keane-Moore M, Buyaner D, Hardy WB, Moorman MA, McIntosh KR, Mosca JD: Characterization and functionality of cell surface molecules on human mesenchymal stem cells. J Biomed Sci 2003, 10:228-241.
40. Devine SM, Hoffman R: Role of mesenchymal stem cells in hematopoietic stem cell transplantation. Curr Opin Hematol 2000, 7:358-363.
41. Djouad F, Plence P, Bony C, Tropel P, Apparailly F, Sany J, Noel D, Jorgensen C: Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003, 102:3837-3844.
42. Beyth S, Borovsky Z, Mevorach D, Liebergall M, Gazit Z, Aslan H, Galun E, Rachmilewitz J: Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 2005, 105:2214-2219.
43. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, Grisanti S, Gianni AM: Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002, 99:3838-3843.
44. Guinan EC, Gribben JG, Boussiotis VA, Freeman GJ, Nadler LM: Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood 1994, 84:3261-3282.
45. Steinman RM, Nussenzweig MC: Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci U S A 2002, 99:351-358.
46. Mills KH: Regulatory T cells: friend or foe in immunity to infection? Nat Rev Immunol 2004, 4:841-855.
47. Steinman RM: The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991, 9:271-296.
48. Steinman RM, Inaba K, Turley S, Pierre P, Mellman I: Antigen capture, processing, and presentation by dendritic cells: recent cell biological studies. Hum Immunol 1999, 60:562-567.
49. Mahon BP, Katrak K, Nomoto A, Macadam AJ, Minor PD, Mills KHG: Poliovirus-specific CD4+ Th1 clones with both cytotoxic and helper activity mediate protective humoral immunity against a lethal poliovirus infection in transgenic mice expressing the human poliovirus receptor. J Exp Med 1995, 181:1285-1292.
50. Thompson C, Powrie F: Regulatory T cells. Curr Opin Pharmacol 2004, 4:408-414.
51. Wood KJ, Jones ND, Bushell AR, Morris PJ: Alloantigen-induced specific immunological unresponsiveness. Philos Trans R Soc Lond B Biol Sci 2001, 356:665-680.
52. Glennie S, Soeiro I, Dyson PJ, Lam EW, Dazzi F: Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 2005, 105:2821-2827.
53. Wells AD, Walsh MC, Bluestone JA, Turka LA: Signaling through CD28 and CTLA-4 controls two distinct forms of T cell anergy. J Clin Invest 2001, 108:895-903.
54. Otten GR, Germain RN: Split anergy in a CD8+ T cell: receptor-dependent cytolysis in the absence of interleukin-2 production. Science 1991, 251:1228-1231.
55. Nash AA, Ashford NP: Split T-cell tolerance in herpes simplex virus-infected mice and its implication for anti-viral immunity. Immunology 1982, 45:761-767.
56. Martinez C, Smith JM: Split Tolerance. Nature 1964, 202:508-509.
57. Masson D, Tschopp J: A family of serine esterases in lytic granules of cytolytic T lymphocytes. Cell 1987, 49:679-685.
58. Ljunggren HG, Karre K: In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today 1990, 11:237-244.
59. Rasmusson I, Ringden O, Sundberg B, Le Blanc K: Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 2003, 76:1208-1213.
60. Dormady SP, Bashayan O, Dougherty R, Zhang XM, Basch RS: Immortalized multipotential mesenchymal cells and the hematopoietic microenvironment. J Hematother Stem Cell Res 2001, 10:125-140.
61. Zhang Y, Li CD, Jiang XX, Li HL, Tang PH, Mao N: Comparison of mesenchymal stem cells from human placenta and bone marrow. Chin Med J (Engl) 2004, 117:882-887.
62. Haynesworth SE, Baber MA, Caplan AI: Cytokine expression by human marrow-derived mesenchymal progenitor cells in vitro: effects of dexamethasone and IL-1 alpha. J Cell Physiol 1996, 166:585-592.
63. Silva WAJ, Covas DT, Panepucci RA, Proto-Siqueira R, Siufi JL, Zanette DL, Santos AR, Zago MA: The profile of gene expression of human marrow mesenchymal stem cells. Stem Cells 2003, 21:661-669.
64. Kuroiwa T, Kakishita E, Hamano T, Kataoka Y, Seto Y, Iwata N, Kaneda Y, Matsumoto K, Nakamura T, Ueki T, Fujimoto J, Iwasaki T: Hepatocyte growth factor ameliorates acute graft-versus-host disease and promotes hematopoietic function. J Clin Invest 2001, 107:1365-1373.
65. Taniguchi F, Harada T, Deura I, Iwabe T, Tsukihara S, Terakawa N: Hepatocyte growth factor promotes cell proliferation and inhibits progesterone secretion via PKA and MAPK pathways in a human granulosa cell line. Mol Reprod Dev 2004, 68:335-344.
66. Xin X, Yang S, Ingle G, Zlot C, Rangell L, Kowalski J, Schwall R, Ferrara N, Gerritsen ME: Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Am J Pathol 2001, 158:1111-1120.
67. Ono I, Yamashita T, Hida T, Jin HY, Ito Y, Hamada H, Akasaka Y, Ishii T, Jimbow K: Local administration of hepatocyte growth factor gene enhances the regeneration of dermis in acute incisional wounds. J Surg Res 2004, 120:47-55.
68. Chunmeng S, Tianmin C, Yongping S, Xinze R, Yue M, Jifu Q, Shufen L, Hui X, Chengji L: Effects of dermal multipotent cell transplantation on skin wound healing. J Surg Res 2004, 121:13-19.
69. Le Blanc K, Rasmusson I, Gotherstrom C, Seidel C, Sundberg B, Sundin M, Rosendahl K, Tammik C, Ringden O: Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin-activated lymphocytes. Scand J Immunol 2004, 60:307-315.
70. Neuss S, Becher E, Woltje M, Tietze L, Jahnen-Dechent W: Functional expression of HGF and HGF receptor/c-met in adult human mesenchymal stem cells suggests a role in cell mobilization, tissue repair, and wound healing. Stem Cells 2004, 22:405-414.
71. Azuma H, Takahara S, Matsumoto K, Ichimaru N, Wang JD, Moriyama T, Waaga AM, Kitamura M, Otsuki Y, Okuyama A, Katsuoka Y, Chandraker A, Sayegh MH, Nakamura T: Hepatocyte growth factor prevents the development of chronic allograft nephropathy in rats. J Am Soc Nephrol 2001, 12:1280-1292.
72. Rasmusson I, Ringden O, Sundberg B, Le Blanc K: Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp Cell Res 2005, in press:.
73. Asseman C, Powrie F: Interleukin 10 is a growth factor for a population of regulatory T cells. Gut 1998, 42:157-158.
74. Ennis DP, Cassidy JP, Mahon BP: Prior Bordetella pertussis infection modulates allergen priming and the severity of airway pathology in a murine model of allergic asthma. Clin Exp Allergy 2004, 34:1488-1497.
75. Mahon BP, Ryan M, Griffin F, McGuirk P, Mills KHG: IL-12 is produced by macrophages in response to live or killed Bordetella pertussis and enhances the efficacy of an acellular pertussis vaccine by promoting the induction of Th1 cells. Infect Immun 1996, 64:5295-5301.
76. Flynn MA, Casey DG, Todryk SM, Mahon BP: Efficient delivery of small interfering RNA for inhibition of IL-12p40 expression in vivo. Journal of Inflammation 2004, 1:4.
77. Pretolani M, Goldman M: IL-10: a potential therapy for allergic inflammation. Immunol Today 1997, 18:277-280.
78. Higgins SC, Lavelle EC, McCann C, Keogh B, McNeela E, Byrne P, O'Gorman B, Jarnicki A, McGuirk P, Mills KH: Toll-like receptor 4-mediated innate IL-10 activates antigen-specific regulatory T cells and confers resistance to Bordetella pertussis by inhibiting inflammatory pathology. J Immunol 2003, 171:3119-3127.
79. McGuirk P, Mills KHG: Direct anti-inflammatory effect of a bacterial virulence factor:IL-10-dependent suppression of IL-12 production by filamentous haemagglutinin from Bordetella pertussis. Eur J Immunol 2000, 30:415-422.
80. Gollnick SO, Cheng HL, Grande CC, Thompson D, Tomasi TB: Effects of transforming growth factor-beta on bone marrow macrophage Ia expression induced by cytokines. J Interferon Cytokine Res 1995, 15:485-491.
81. Ruegemer JJ, Ho SN, Augustine JA, Schlager JW, Bell MP, McKean DJ, Abraham RT: Regulatory effects of transforming growth factor-beta on IL-2- and IL-4-dependent T cell-cycle progression. J Immunol 1990, 144:1767-1776.
82. Arikawa T, Omura K, Morita I: Regulation of bone morphogenetic protein-2 expression by endogenous prostaglandin E2 in human mesenchymal stem cells. J Cell Physiol 2004, 200:400-406.
83. Roper RL, Ludlow JW, Phipps RP: Prostaglandin E2 inhibits B lymphocyte activation by a cAMP-dependent mechanism: PGE-inducible regulatory proteins. Cell Immunol 1994, 154:296-308.
84. Akasaki Y, Liu G, Chung NH, Ehtesham M, Black KL, Yu JS: Induction of a CD4+ T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma. J Immunol 2004, 173:4352-4359.
85. Colgan SP: Lipid mediators in epithelial cell-cell interactions. Cell Mol Life Sci 2002, 59:754-760.
86. Munn DH, Mellor AL, Rossi M, Young JW: Dendritic cells have the option to express IDO-mediated suppression or not. Blood 2005, 105:2618.
87. Munn DH, Mellor AL: IDO and tolerance to tumors. Trends Mol Med 2004, 10:15-18.
88. Mellor AL, Munn DH: Tryptophan catabolism prevents maternal T cells from activating lethal anti-fetal immune responses. J Reprod Immunol 2001, 52:5-13.
89. Mellor AL, Munn DH: IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004, 4:762-774.
90. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D: Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004, 103:4619-4621.
91. Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, Ferrara GB: Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med 2002, 196:459-468.
92. Strand S, Galle PR: Immune evasion by tumours: involvement of the CD95 (APO-1/Fas) system and its clinical implications. Mol Med Today 1998, 4:63-68.
93. Mitra R, Singh S, Khar A: Antitumour immune responses. Expert Rev Mol Med 2003, 2003:1-22.
94. Fujiwara K, Higashi T, Nouso K, Nakatsukasa H, Kobayashi Y, Uemura M, Nakamura S, Sato S, Hanafusa T, Yumoto Y, Naito I, Shiratori Y: Decreased expression of B7 costimulatory molecules and major histocompatibility complex class-I in human hepatocellular carcinoma. J Gastroenterol Hepatol 2004, 19:1121-1127.
95. Jung D, Hilmes C, Knuth A, Jaeger E, Huber C, Seliger B: Gene transfer of the Co-stimulatory molecules B7-1 and B7-2 enhances the immunogenicity of human renal cell carcinoma to a different extent. Scand J Immunol 1999, 50:242-249.
96. Ninomiya T, Akbar SM, Masumoto T, Horiike N, Onji M: Dendritic cells with immature phenotype and defective function in the peripheral blood from patients with hepatocellular carcinoma. J Hepatol 1999, 31:323-331.
97. Rosenberg SA: The development of new immunotherapies for the treatment of cancer using interleukin-2. A review. Ann Surg 1988, 208:121-135.
98. Nakamura K, Kitani A, Fuss I, Pedersen A, Harada N, Nawata H, Strober W: TGF-beta 1 plays an important role in the mechanism of CD4+CD25+ regulatory T cell activity in both humans and mice. J Immunol 2004, 172:834-842.
99. Ranges GE, Figari IS, Espevik T, Palladino MAJ: Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha. J Exp Med 1987, 166:991-998.
100. van der Pouw Kraan TC, Boeije LC, Snijders A, Smeenk RJ, Wijdenes J, Aarden LA: Regulation of IL-12 production by human monocytes and the influence of prostaglandin E2. Ann N Y Acad Sci 1996, 795:147-157.
101. Chang HL, Gillett N, Figari I, Lopez AR, Palladino MA, Derynck R: Increased transforming growth factor beta expression inhibits cell proliferation in vitro, yet increases tumorigenicity and tumor growth of Meth A sarcoma cells. Cancer Res 1993, 53:4391-4398.
102. Walker PR, Saas P, Dietrich PY: Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back. J Immunol 1997, 158:4521-4524.
103. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F: The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996, 184:1075-1082.
104. Niehans GA, Brunner T, Frizelle SP, Liston JC, Salerno CT, Knapp DJ, Green DR, Kratzke RA: Human lung carcinomas express Fas ligand. Cancer Res 1997, 57:1007-1012.
105. Liu J, Lu XF, Wan L, Li YP, Li SF, Zeng LY, Zeng YZ, Cheng LH, Lu YR, Cheng JQ: Suppression of human peripheral blood lymphocyte proliferation by immortalized mesenchymal stem cells derived from bone marrow of Banna Minipig inbred-line. Transplant Proc 2004, 36:3272-3275.
106. Mackay AM, Beck SC, Murphy JM, Barry FP, Chichester CO, Pittenger MF: Chondrogenic differentiation of cultured human mesenchymal stem cells from marrow. Tissue Eng 1998, 4:415-428.
107. Murphy JM, Fink DJ, Hunziker EB, Barry FP: Stem cell therapy in a caprine model of osteoarthritis. Arthritis Rheum 2003, 48:3464-3474.
108. Thorpe SJ, Thein SL, Sampietro M, Craig JE, Mahon BP, Huehns ER: Immunochemical estimation of haemoglobin types in red blood cells by FACS analysis. British Journal of Haematology 1994, 87:125-131.
109. McGuirk P, Mahon BP, Griffin F, Mills KHG: Compartmentalization of T cell responses following respiratory infection with Bordetella pertussis: hyporesponsiveness of lung T cells is associated with modulated expression of the costimulatory molecule CD28. European Journal of Immunology 1998, 28:153-163.
110. Ryan M, McCathy L, Mahon BP, Rappuoli R, Mills KHG: Mechanism of adjuvanticity of pertussis toxin (PT): PT potentiates Th1 and Th2 responses by stimulating regulatory and accessory cytokine secretion and enhancing expression of the co-stimulatory molecules B7-1, B7-2 and CD28. International Immunology 1998, 10:651-662.
111. Yang L, Carbone DP: Tumor-host immune interactions and dendritic cell dysfunction. Adv Cancer Res 2004, 92:13-27.
112. Mapara MY, Sykes M: Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol 2004, 22:1136-1151.